nam/aidsmap, 7 September 2020
A study in which 24 trans women and 24 trans men who were taking gender-affirming hormone therapy were directly observed to take a daily dose of the standard formulation of the HIV prevention medication PrEP found that the levels of the two PrEP drugs tenofovir and emtricitabine were similar to the levels seen in similar cis men and women, and were all above levels associated with efficacy.
This study to some extent addresses concerns raised by a couple of other studies which had suggested that both levels of gender-affirming hormones and levels of PrEP could be lower in trans people taking PrEP, due to drug-drug interactions.